Previous studies have shown that abnormal expression of p53 and p16 can be used to identify high-risk endometrial cancer patients with poor prognosis, but this is still poorly used in clinical practice [31]; lower expression of ER and PR is associated with increased tumour-related mortality, but does not improve the prediction of individual mortality levels [32]. Here, TP53 is linked to neoplasm.